Biotechnology

Intellia Therapeutics secures a massive non-dilutive debt facility from OrbiMed, a strategic move to fund its one-time CRISPR therapy for HAE.

A breakthrough in proteomics allows Nautilus Biotechnology to map individual disease-linked proteins, promising to revolutionize diagnostics and drug discovery.

A landmark bill in Congress and nationwide walks aim to channel millions into R&D for a genetic disorder affecting 500,000 Americans, creating a new roadmap for a cure.

With over a billion in the bank, Spyre Therapeutics is hitting the investor circuit. But cash is only half the story. Can upcoming data validate its ambitious strategy?

A small biotech is making a bold leap, leveraging its heart disease expertise to tackle Alzheimer's and Parkinson's with a novel class of brain drugs.

Cipla and Qilu are teaming up to launch a biosimilar for Keytruda, the world's top cancer drug, signaling a major shift in patient access and market dynamics.

Cape Fear BioCapital's new fund isn't just about capital. It's a strategic infusion of operator experience and partnerships set to transform NC's biotech landscape.

As advanced therapies reshape medicine, the race to control their complex supply chains heats up. Resonant's latest acquisition places it at the heart of Europe's booming market.

As Claris Bio courts investors, it's not just capital on the line. At stake is a first-of-its-kind eye drop for a rare, blinding disease.

Tangram Therapeutics signals a major strategic push, advancing its novel MASH drug into patient trials while hiring a veteran CDO to steer its pipeline.

The Israeli biotech firm gained crucial FDA feedback for its personalized therapy, NewRal. But in a field laden with failure, is this a true breakthrough?

Northway Biotech's new Vilnius hub isn't just a factory; it's a strategic move to dominate Europe's advanced therapy market. A deep dive into the investment.

Facing delisting, BioRestorative executes another reverse split. We dive into whether this financial maneuver can sustain it or just delays the inevitable.

The prestigious Prix Galien awards debut in Seoul, cementing South Korea's status as a life sciences leader and spotlighting a wave of homegrown innovation.

Drs. Zoghbi and Bird win the prestigious Horwitz Prize for turning Rett syndrome from an untreatable mystery into a reversible condition, offering new hope.

A new deal between Owkin and Boehringer Ingelheim isn't just a partnership; it's a look at the future where AI scientists and deep data drive innovation.

As Stoke prepares for a key investor conference, its lead drug zorevunersen nears a pivotal Phase 3 readout, promising a new era for patients and the RNA platform.

A new US patent allowance for Purple Biotech's modular CAPTN-3 platform bolsters its strategic position, promising safer, more precise antibody cancer treatments.

Resalis Therapeutics poaches a top clinical leader from Novo Nordisk to steer its novel RNA-based obesity drug, RES-010, through clinical trials.

Thai researchers are turning fat into insulin-producing cells to cure pet diabetes. But can this breakthrough navigate the path from lab to leash?